A review of the clinical pharmacokinetics of polymyxin b

Sean N. Avedissian, Jiajun Liu, Nathaniel J. Rhodes, Andrew Lee, Gwendolyn M. Pais, Alan R. Hauser, Marc H. Scheetz

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Polymyxin B remains an antibiotic of last resort because of its toxicities. Although newer therapies are becoming available, it is anticipated that resistance to these agents will continue to emerge, and understanding the safest and most efficacious manner to deliver polymyxin B will remain highly important. Recent data have demonstrated that polymyxin B may be less nephrotoxic than colistin. Pharmacokinetically, polymyxin B is primarily eliminated via non-renal pathways, and most do not recommend adjusting the dose for renal impairment. However, some recent studies suggest a weak relationship between polymyxin B clearance and patient creatinine clearance. This review article will describe the clinical pharmacokinetics of polymyxin B and address relevant issues in chemistry and assays available.

Original languageEnglish (US)
Article number31
JournalAntibiotics
Volume8
Issue number1
DOIs
StatePublished - Mar 2019

Fingerprint

Polymyxins
Polymyxin B
Pharmacokinetics
Colistin
Toxicity
Assays
Creatinine
Anti-Bacterial Agents
Kidney

Keywords

  • Pharmacokinetics
  • Polymyxin B

ASJC Scopus subject areas

  • Microbiology
  • Biochemistry
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Avedissian, S. N., Liu, J., Rhodes, N. J., Lee, A., Pais, G. M., Hauser, A. R., & Scheetz, M. H. (2019). A review of the clinical pharmacokinetics of polymyxin b. Antibiotics, 8(1), [31]. https://doi.org/10.3390/antibiotics8010031

A review of the clinical pharmacokinetics of polymyxin b. / Avedissian, Sean N.; Liu, Jiajun; Rhodes, Nathaniel J.; Lee, Andrew; Pais, Gwendolyn M.; Hauser, Alan R.; Scheetz, Marc H.

In: Antibiotics, Vol. 8, No. 1, 31, 03.2019.

Research output: Contribution to journalArticle

Avedissian, SN, Liu, J, Rhodes, NJ, Lee, A, Pais, GM, Hauser, AR & Scheetz, MH 2019, 'A review of the clinical pharmacokinetics of polymyxin b', Antibiotics, vol. 8, no. 1, 31. https://doi.org/10.3390/antibiotics8010031
Avedissian, Sean N. ; Liu, Jiajun ; Rhodes, Nathaniel J. ; Lee, Andrew ; Pais, Gwendolyn M. ; Hauser, Alan R. ; Scheetz, Marc H. / A review of the clinical pharmacokinetics of polymyxin b. In: Antibiotics. 2019 ; Vol. 8, No. 1.
@article{ce085e9c5e0a426e999aeb81f372e9da,
title = "A review of the clinical pharmacokinetics of polymyxin b",
abstract = "Polymyxin B remains an antibiotic of last resort because of its toxicities. Although newer therapies are becoming available, it is anticipated that resistance to these agents will continue to emerge, and understanding the safest and most efficacious manner to deliver polymyxin B will remain highly important. Recent data have demonstrated that polymyxin B may be less nephrotoxic than colistin. Pharmacokinetically, polymyxin B is primarily eliminated via non-renal pathways, and most do not recommend adjusting the dose for renal impairment. However, some recent studies suggest a weak relationship between polymyxin B clearance and patient creatinine clearance. This review article will describe the clinical pharmacokinetics of polymyxin B and address relevant issues in chemistry and assays available.",
keywords = "Pharmacokinetics, Polymyxin B",
author = "Avedissian, {Sean N.} and Jiajun Liu and Rhodes, {Nathaniel J.} and Andrew Lee and Pais, {Gwendolyn M.} and Hauser, {Alan R.} and Scheetz, {Marc H.}",
year = "2019",
month = "3",
doi = "10.3390/antibiotics8010031",
language = "English (US)",
volume = "8",
journal = "Antibiotics",
issn = "2079-6382",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

TY - JOUR

T1 - A review of the clinical pharmacokinetics of polymyxin b

AU - Avedissian, Sean N.

AU - Liu, Jiajun

AU - Rhodes, Nathaniel J.

AU - Lee, Andrew

AU - Pais, Gwendolyn M.

AU - Hauser, Alan R.

AU - Scheetz, Marc H.

PY - 2019/3

Y1 - 2019/3

N2 - Polymyxin B remains an antibiotic of last resort because of its toxicities. Although newer therapies are becoming available, it is anticipated that resistance to these agents will continue to emerge, and understanding the safest and most efficacious manner to deliver polymyxin B will remain highly important. Recent data have demonstrated that polymyxin B may be less nephrotoxic than colistin. Pharmacokinetically, polymyxin B is primarily eliminated via non-renal pathways, and most do not recommend adjusting the dose for renal impairment. However, some recent studies suggest a weak relationship between polymyxin B clearance and patient creatinine clearance. This review article will describe the clinical pharmacokinetics of polymyxin B and address relevant issues in chemistry and assays available.

AB - Polymyxin B remains an antibiotic of last resort because of its toxicities. Although newer therapies are becoming available, it is anticipated that resistance to these agents will continue to emerge, and understanding the safest and most efficacious manner to deliver polymyxin B will remain highly important. Recent data have demonstrated that polymyxin B may be less nephrotoxic than colistin. Pharmacokinetically, polymyxin B is primarily eliminated via non-renal pathways, and most do not recommend adjusting the dose for renal impairment. However, some recent studies suggest a weak relationship between polymyxin B clearance and patient creatinine clearance. This review article will describe the clinical pharmacokinetics of polymyxin B and address relevant issues in chemistry and assays available.

KW - Pharmacokinetics

KW - Polymyxin B

UR - http://www.scopus.com/inward/record.url?scp=85064241033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064241033&partnerID=8YFLogxK

U2 - 10.3390/antibiotics8010031

DO - 10.3390/antibiotics8010031

M3 - Article

C2 - 30909507

AN - SCOPUS:85064241033

VL - 8

JO - Antibiotics

JF - Antibiotics

SN - 2079-6382

IS - 1

M1 - 31

ER -